Hemogenyx Shares Jump After Request of FDA Meeting for Leukemia Therapy
13 Dezembro 2021 - 6:45AM
Dow Jones News
By Jaime Llinares Taboada
Shares in Hemogenyx Pharmaceuticals PLC rose Monday after the
company said it has applied for a Pre-Investigational New Drug
application meeting with the U.S. Food and Drug Administration for
its HEMO-CAR-T leukemia therapy.
The biopharmaceutical group said the meeting is to enable it to
complete planning of clinical trials for the product candidate, and
to submit an Investigational New Drug Application.
"This is a vital next step on a direct path toward clinical
trials for one of our leading product candidates," Chief Executive
Vladislav Sandler said.
Shares at 0903 GMT were up 17% at 2.10 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
December 13, 2021 04:30 ET (09:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Hemogenyx Pharmaceuticals (LSE:HEMO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
